Trial · NCT00658411
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
NCT00658411, Not applicable, Terminated, Dana-Farber Cancer Institute; results first posted 2013-04-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation. Trials, record NCT00658411. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00658411
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
- NCT number
- NCT00658411
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 5 participants, actual
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Interventions
- deferoxamine
- First posted
- 2008-04-15
- Last updated
- 2013-04-09
- Results first posted
- 2013-04-09
- Limitations and caveats
- The number of patients enrolled on this study is far too small to draw reliable conclusions.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. | Baseline , 6 month, 1 year | All patients meeting the criteria for Severe iron overload as defined by BOTH: ferritin ≥ 1000 ng/ml and liver iron content(LIC) ≥ 5 mg/gdw were enrolled and received chelation therapy with Deferoxamine. All patients who received chelation therapy were monitored for grade 3 or above toxicity Attributable to Deferoxamine(grades defined by the CTCAE Version 3). The number of participants with grade 3 or higher toxicities were measured and used to determine the safety of chelation therapy. |
| Secondary | 1-year Post-Transplant Survival | 1 year | Survival information for the 5 patients who were treated with deferoxamine was collected. This information was used to determine transplant-related mortality, relapse, disease-free and overall survival. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. | Baseline , 6 month, 1 year | Patients who met criteria for iron overload pre-transplant, as defined by the protocol, were enrolled on study for chelation therapy. Those patients who received therapy were monitored for toxicities using the CTCAE version 3.0. | Participants | NUMBER |
| SECONDARY | 1-year Post-Transplant Survival | 1 year | Stopped early for poor accrual | participants | NUMBER |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. | Deferoxamine | Baseline | 5 | 9.8 | Participants |
| Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. | Deferoxamine | 6 month | 0 | Participants | |
| Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. | Deferoxamine | 1 year | 0 | Participants | |
| 1-year Post-Transplant Survival | Transplant-Related Mortality (Deferoxamine) | 0 | participants | ||
| 1-year Post-Transplant Survival | Relapse (Deferoxamine) | 0 | participants | ||
| 1-year Post-Transplant Survival | Disease-Free Survival (Deferoxamine) | 5 | participants | ||
| 1-year Post-Transplant Survival | Overall Survival (Deferoxamine) | 0 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Patients | 5 | |
| Overall Study | COMPLETED | All Patients | 5 | |
| Overall Study | NOT COMPLETED | All Patients | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Hypotension | Vascular disorders | Deferoxamine | 1 | 5 | 5 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Deferoxamine | ||
| Total, other adverse events | Deferoxamine | 0 | 5 |
| Total, serious adverse events | Deferoxamine | 1 | 5 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22609885 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00658411
GET https://conductscience.org/api/trials/v1/NCT00658411/registered